Sunbed companies have been warned that their advertising must not minimise the risk of cancer or suggest unsupported health benefits. The Advertising Standards Authority, the UK body that oversees advertising standards, has made clear that firms promoting tanning devices cannot present exposure as harmless or imply that the risks are negligible. The warning also covers claims that sunbeds can treat skin conditions or improve mental health when such statements are misleading.
The intervention places renewed attention on how commercial tanning services communicate with customers, particularly online and on social media, where short promotional messages can blur the line between marketing and health advice. Any suggestion that indoor tanning is a wellness treatment carries regulatory significance because it may influence decisions about exposure to ultraviolet radiation. Links between UV exposure and skin cancer are widely recognised by public health authorities, and the World Health Organization classifies ultraviolet-emitting tanning devices as a cancer hazard.
The watchdog’s position does not prevent businesses from advertising legal services, but it restricts the way those services are framed. Promotional material cannot downplay cancer risk, present tanning as a safe route to cosmetic change, or use claims about medical treatment without adequate substantiation. References to skin conditions are especially sensitive because consumers may interpret them as therapeutic advice. Claims linked to mental health are also under scrutiny when they suggest benefits that advertising rules do not allow companies to state without robust evidence.
The issue matters beyond the tanning industry because it reflects a broader regulatory concern over health-related marketing. Advertisers in sectors connected to beauty, lifestyle and wellbeing often use language associated with confidence, mood and self-care. When those messages concern products or services with recognised health risks, regulators require a higher level of caution. For consumers, the watchdog’s warning is a reminder to distinguish commercial promotion from medical guidance. For operators, it signals that compliance depends not only on what is sold, but on how the risks and alleged benefits are described.
